FY2026 EPS Estimates for Roche Decreased by Erste Group Bank

Key Points

• Erste Group Bank trimmed its FY2026 EPS estimate for Roche to $3.16 (from $3.19) and forecasts FY2027 EPS of $3.36, versus a consensus current-year estimate of $2.81 per share.
• Analyst sentiment is mixed—five Buys, five Holds and one Sell—leaving an average rating of Hold and an average price target of $57.00.
• Roche ADRs (RHHBY) opened at $49.35 and were down about 1.3%, trading within a one-year range of $34.75–$60.85.

Roche Holding AG (OTCMKTS:RHHBY - Free Report) - Investment analysts at Erste Group Bank decreased their FY2026 earnings estimates for Roche in a research note issued to investors on Thursday, April 2nd. Erste Group Bank analyst H. Engel now expects that the company will post earnings per share of $3.16 for the year, down from their prior estimate of $3.19. The consensus estimate for Roche's current full-year earnings is $2.81 per share. Erste Group Bank also issued estimates for Roche's FY2027 earnings at $3.36 EPS.

A number of other equities analysts have also commented on RHHBY. Barclays raised shares of Roche from an "equal weight" rating to an "overweight" rating in a research note on Tuesday, January 6th. HSBC reaffirmed a "buy" rating and issued a $57.00 price objective on shares of Roche in a research note on Wednesday, December 10th. Morgan Stanley reaffirmed an "underweight" rating on shares of Roche in a research note on Wednesday, February 4th. Citigroup assumed coverage on shares of Roche in a research note on Tuesday, January 27th. They issued a "buy" rating for the company. Finally, Zacks Research raised shares of Roche from a "strong sell" rating to a "hold" rating in a research note on Monday, January 5th. Five research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $57.00.

Roche Stock Down 1.3%

Shares of OTCMKTS:RHHBY opened at $49.35 on Wednesday. Roche has a 1-year low of $34.75 and a 1-year high of $60.85. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38. The company has a 50 day moving average price of $54.45 and a 200 day moving average price of $50.04.

Institutional Investors Weigh In On Roche

Institutional investors have recently modified their holdings of the stock. Curio Wealth LLC acquired a new stake in shares of Roche during the 3rd quarter valued at $25,000. Oakworth Capital Inc. bought a new position in shares of Roche during the 3rd quarter valued at $57,000. Salomon & Ludwin LLC raised its holdings in shares of Roche by 256.6% during the 3rd quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company's stock valued at $129,000 after purchasing an additional 2,053 shares in the last quarter. Atlas Capital Advisors Inc. bought a new position in shares of Roche during the 4th quarter valued at $192,000. Finally, Douglass Winthrop Advisors LLC bought a new position in shares of Roche during the 3rd quarter valued at $201,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY OTCMKTS: RHHBY.

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.